MRM open to partnerships after lead candidate impresses in PhIIa ulcerative colitis trial

19 Sep 2023
endpts.com
Clinical ResultPhase 2Microbial therapy
MRM Health’s microbiome consortium therapy for ulcerative colitis has shown promise in a Phase IIa trial, triggering plans for late-stage development and potential partnerships.
The Belgian biotech’s study set the treatment, dubbed MH002, against placebo in 45 people with mild-to-moderate UC.
MH002 produced a 12% improvement in the Mayo Endoscopic Severity score, while the score worsened by 5% with placebo (p=0.05). The treatment also hit significance in the endpoint of stool consistency improvement after two weeks (p=0.006).
MRM open to partnerships after lead candidate impresses in PhIIa ulcerative colitis trial
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.